Last reviewed · How we verify
Sham Avastin Intravitreal Injection — Competitive Intelligence Brief
phase 3
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Sham Avastin Intravitreal Injection (Sham Avastin Intravitreal Injection) — Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA. This is a sham (placebo) intravitreal injection used as a control in clinical trials, containing no active pharmaceutical ingredient.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sham Avastin Intravitreal Injection TARGET | Sham Avastin Intravitreal Injection | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sham Avastin Intravitreal Injection CI watch — RSS
- Sham Avastin Intravitreal Injection CI watch — Atom
- Sham Avastin Intravitreal Injection CI watch — JSON
- Sham Avastin Intravitreal Injection alone — RSS
Cite this brief
Drug Landscape (2026). Sham Avastin Intravitreal Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/sham-avastin-intravitreal-injection. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab